Please scan for our contact infomation
Monoclonal antibody can clear β-amyloid protein in brain
View:135 Time:2013-Mar-07 14:50
According to the longtime study, monoclonal antibody can clear β-amyloid protein in brain of the Alzheimers disease patients, this result concluded by the researchers.
The researchers failed to observe indicators of cognitive changes consistent with amyloid changes, but they think the time is too short of the sample size is too small, and treatment-related.
Gantenerumab is a fully humanized monoclonal antibody, and β-amyloid protein plaque-specific binding. The study recruited a mild to moderate Alzheimers disease patients, intravenous injection of the antibody 2 to 7 times and placebo were compared. Injected once every four weeks, 60 or 200 mg per injection. The report is the result of which 16 patients. At baseline and during treatment, these patients the brain β-amyloid deposition site and quantity is detected by positron emission segment tomography (PET).
The research team found when the experiment is to carry out the new collection of human glial cells, gantenerumab reduce amyloid levels might phagocytosis. This finding suggests that, gantenerumab may not significantly alter the vascular permeability (via the case of inflammation or blocked β-amyloid protein to clear the passage), which produce the reduced amyloid protein level.
The end of treatment, the placebo patients, PET standardized the absorption value ratio (SUVR) average increase over baseline 21%, 60 mg the PET-SUVR gantenerumab group of 6 patients increased by an average of 5%, the 200 mg gantenerumab Group 6patients dropped by an average of 15%. The difference between the various regions of the brain in such a group are present, the only exception is the pons, and the latter is known to be less amyloid deposition region. 2 to 7 times after injection, gantenerumab quickly apparent effect of amyloid deposition.
The result of monoclonal antibody can clear β-amyloid protein in brain is encouraged, but the researchers think the scale of this study is too small, and after reduce the amyloid content, the subsequent clinical significance remains unknown.